Protagonist Therapeutics Inc PTGX

NAS: PTGX | ISIN: US74366E1029 30/04/2025

45,82 USD (+0,44%)

(+0,44%) 30/04/2025

Grafiek Protagonist Therapeutics Inc

Grafiek Protagonist Therapeutics Inc

1 dag1d 0,44%
1 week1w 2,16%
1 maand1m -2,26%
3 maanden3m 23,17%
6 maanden6m -2,01%
1 jaar1j 79,26%
5 jaar5j 592,15%

Protagonist Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

27 juni 2024 · Protagonist Therapeutics Set to Join S&P SmallCap 600 · Persbericht

12 mei 2023 · Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 · Persbericht

11 mei 2023 · Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference · Persbericht

11 mei 2023 · Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association · Persbericht

4 mei 2023 · Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

7 maart 2023 · Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis · Persbericht

21 december 2022 · Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2022 · Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit · Persbericht

16 november 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

8 november 2022 · Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

Profiel Protagonist Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 99

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe